Autifony Therapeutics Limited
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
4
Ending by 2030
Dec 2030
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 15, 2027The maintenance fee for Compounds (US 9,133,175) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
- 1 fee due May 24, 2027The maintenance fee for Hydantoin Derivatives as KV3 Inhibitors (US 9,193,704) comes due May 24, 2027. Unpaid by Nov 24, 2027, it lapses early.
- 1 fee due Jun 22, 2027The maintenance fee for Imidazolidinedione Derivatives (US 9,216,967) comes due Jun 22, 2027. Unpaid by Dec 22, 2027, it lapses early.
- 1 fee due Aug 11, 2027The maintenance fee for Compounds (US 10,555,945) comes due Aug 11, 2027. Unpaid by Feb 11, 2028, it lapses early.
- 3 fees due Oct 2 to 28, 2027 · next Oct 2
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Nov 10 US 12,790,330 Potassium Channel Modulators
- 1 term has ended since Aug 23, 2026
- Aug 28 US 10,058,551 Imidazolidinedione Derivatives · lapsed on the fee record
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,216,967 | Imidazolidinedione Derivatives In force · High confidence | In force | High confidence | |
| US 9,849,131 | Imidazolidinedione Derivatives In force · High confidence | In force | High confidence | |
| US 10,632,118 | Imidazolidinedione Derivatives In force · High confidence | In force | High confidence | |
| US 8,722,695 | Imidazolidinedione Derivatives In force · High confidence | In force | High confidence | |
| US 10,265,316 | Hydantoin Derivatives Useful as KV3 Inhibitors In force · Low confidence | In force | Low confidence | |
| US 11,197,859 | Hydantoin Derivatives Useful as KV3 Inhibitors In force · Medium confidence | In force | Medium confidence | |
| US 11,583,527 | Hydantoin Derivatives Useful as KV3 Inhibitors In force · Medium confidence | In force | Medium confidence | |
| US 9,193,704 | Hydantoin Derivatives as KV3 Inhibitors In force · High confidence | In force | High confidence | |
| US 9,346,790 | Hydantoin Derivatives Useful as KV3 Inhibitors In force · High confidence | In force | High confidence | |
| US 9,133,175 | Compounds In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 24: 3 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 5 abandoned · 2 no status recorded